Benefit of sodium-glucose cotransporter-2 inhibitors on survival outcome is related to the type of heart failure: A meta-analysis. (May 2022)

• Record Type: Journal Article
• Authors: Zhao, Lingyue; Guo, Wenqin; Huang, Weichao; Wang, Lili; Huang, Siquan
• Is Part Of: Diabetes research and clinical practice. Volume 187(2022)
• Publication Date: 2022-05
• Subjects: SGLT-2 inhibitor -- Heart failure with preserved ejection fraction -- Heart failure with reduced ejection fraction -- Cardiac death -- Rehospitalization for heart failure -- Meta-analysis; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2022.109871
• Languages: English
• ISSNs: 0168-8227

Abstract

Abstract: Aims: This meta-analysis aimed to evaluate the efficacy of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in different types of heart failure (HF). Methods: Randomized controlled trials (RCTs) comparing SGLT-2 inhibitors with placebo in patients with HF were searched in PubMed, the Cochrane Library database, and clinicaltrials.gov . A random-effects model was used for evidence synthesis. The primary endpoint was cardiac death. Results: We included 13 studies (12 RCTs). In patients with HF with preserved ejection fraction (HFpEF), SGLT-2 inhibitors reduced the composite endpoint of cardiac death or rehospitalization because of HF (HHF) (HR: 0.78, 95% CI: 0.70–0.87, I 2 = 0%, P < 0.001) and that of HHF (HR: 0.74; 95% CI: 0.64–0.85, I 2 = 0%, P < 0.001) but not that of cardiac death (HR: 1.01, 95% CI: 0.80–1.28, I 2 = 23.9%, P = 0.943). In patients with HF with reduced EF (HFrEF), SGLT-2 inhibitors reduced the composite endpoint of cardiac death or HHF (HR: 0.75, 95% CI: 0.69–0.82, I 2 = 0%, P < 0.001) and the individual endpoints of cardiac death (HR: 0.84, 95% CI: 0.75–0.95, I 2 = 0%, P = 0.007) and HHF (HR: 0.69, 95% CI: 0.62–0.77, I 2 = 0%, P < 0.001). Conclusions: SGLT-2 inhibitors reduced the risk of cardiac death in patients with HFrEF but not in those with HFpEF.